Guangxi University of Chinese Medicine, Nanning, Guangxi, China
Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
BMJ Open. 2024 Nov 20;14(11):e087164. doi: 10.1136/bmjopen-2024-087164.
The presence of cognitive dysfunction notably affects the quality of life in individuals diagnosed with Parkinson's disease (PD) and is often recognised as a non-motor symptom. Comprehensive studies have shown the possible advantages of hyperbaric oxygen therapy (HBOT) in alleviating cognitive deficits in these individuals. This systematic review aims to investigate the practicality of incorporating HBOT within a more extensive therapeutic framework for PD, with a specific focus on cognitive symptoms.
A comprehensive literature review will be conducted utilising various databases such as PubMed and Cochrane Library and so on. The duration of the search will encompass the entire timeline from the initiation of each database up to 1 April 2024. This investigation seeks to uncover randomised controlled trials that explore the efficacy and safety of HBOT in patients with PD who are facing cognitive impairments. The authors' autonomous screening and extraction of data will facilitate the attainment of impartial results. The assessment of possible biases will be conducted using the Cochrane risk-of-bias tool, while statistical analyses will be executed with RevMan V.5.3 and Stata V.15.0.
As this review synthesises and evaluates previously conducted studies, the requirement for ethical approval is not applicable. The findings from this review will be shared via academic publications, comprehensive reports and presentations at pertinent conferences.
CRD42024504763.
认知功能障碍的存在显著影响了被诊断患有帕金森病(PD)的个体的生活质量,并且通常被认为是一种非运动症状。综合研究表明,高压氧治疗(HBOT)在缓解这些个体的认知缺陷方面可能具有优势。本系统评价旨在研究将 HBOT 纳入更广泛的 PD 治疗框架的实用性,重点关注认知症状。
将利用 PubMed 和 Cochrane Library 等各种数据库进行全面的文献综述。搜索的时间范围将涵盖从每个数据库启动到 2024 年 4 月 1 日的整个时间线。本研究旨在发现探索 HBOT 在面临认知障碍的 PD 患者中的疗效和安全性的随机对照试验。作者自主筛选和提取数据将有助于获得公正的结果。使用 Cochrane 偏倚风险工具评估可能存在的偏倚,而使用 RevMan V.5.3 和 Stata V.15.0 进行统计分析。
由于本综述综合和评估了以前进行的研究,因此不需要伦理批准。本综述的结果将通过学术出版物、综合报告和相关会议上的演示进行分享。
PROSPERO 注册号:CRD42024504763。